{
  "protocolSection": {
    "identificationModule": {
      "nctId": "NCT04129320",
      "orgStudyIdInfo": {
        "id": "CP-MGA271-05"
      },
      "organization": {
        "fullName": "MacroGenics",
        "class": "INDUSTRY"
      },
      "briefTitle": "Enoblituzumab Plus MGA012 or MGD013 in Squamous Cell Carcinoma of the Head and Neck",
      "officialTitle": "A Phase 2/3 Open-Label Trial to Evaluate Enoblituzumab in Combination With MGA012 or MGD013 in the First-Line Treatment of Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck"
    },
    "statusModule": {
      "statusVerifiedDate": "2022-02",
      "overallStatus": "WITHDRAWN",
      "whyStopped": "Change in study design",
      "expandedAccessInfo": {
        "hasExpandedAccess": false
      },
      "startDateStruct": {
        "date": "2019-10",
        "type": "ESTIMATED"
      },
      "primaryCompletionDateStruct": {
        "date": "2020-10",
        "type": "ESTIMATED"
      },
      "completionDateStruct": {
        "date": "2022-10",
        "type": "ESTIMATED"
      },
      "studyFirstSubmitDate": "2019-10-14",
      "studyFirstSubmitQcDate": "2019-10-15",
      "studyFirstPostDateStruct": {
        "date": "2019-10-16",
        "type": "ACTUAL"
      },
      "lastUpdateSubmitDate": "2022-02-04",
      "lastUpdatePostDateStruct": {
        "date": "2022-02-08",
        "type": "ACTUAL"
      }
    },
    "sponsorCollaboratorsModule": {
      "responsibleParty": {
        "type": "SPONSOR"
      },
      "leadSponsor": {
        "name": "MacroGenics",
        "class": "INDUSTRY"
      }
    },
    "oversightModule": {
      "oversightHasDmc": true,
      "isFdaRegulatedDrug": true,
      "isFdaRegulatedDevice": false
    },
    "descriptionModule": {
      "briefSummary": "This is an open-label study designed to evaluate safety and efficacy of enoblituzumab in combination with MGA012 or MGD013 in first-line treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN).",
      "detailedDescription": "The study will initially be conducted in 2 modules, Module X (enoblituzumab plus MGA012) and Module Y (enoblituzumab plus MGD013). Enrollment into Modules X and Y, with approximately 30 patients each, will occur independently in a non-randomized fashion. Data from these modules will determine if further evaluation will occur in randomized Module A (Phase 2) and randomized Module B (Phase 3)."
    },
    "conditionsModule": {
      "conditions": [
        "Head and Neck Cancer",
        "Squamous Cell Carcinoma of Head and Neck"
      ],
      "keywords": [
        "SCCHN",
        "head and neck",
        "oropharyngeal",
        "oral cavity",
        "hypopharyngeal",
        "laryngeal cancer",
        "immunotherapy",
        "PD-1",
        "B7-H3",
        "LAG-3"
      ]
    },
    "designModule": {
      "studyType": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "designInfo": {
        "allocation": "NON_RANDOMIZED",
        "interventionModel": "PARALLEL",
        "interventionModelDescription": "Parallel study model refers to concurrent enrollment of non-randomized Modules X and Y.",
        "primaryPurpose": "TREATMENT",
        "maskingInfo": {
          "masking": "NONE"
        }
      },
      "enrollmentInfo": {
        "count": 0,
        "type": "ACTUAL"
      }
    },
    "armsInterventionsModule": {
      "armGroups": [
        {
          "label": "Experimental Arm 1",
          "type": "EXPERIMENTAL",
          "description": "Enoblituzumab plus MGA012",
          "interventionNames": [
            "Biological: enoblituzumab",
            "Biological: MGA012"
          ]
        },
        {
          "label": "Experimental Arm 2",
          "type": "EXPERIMENTAL",
          "description": "Enoblituzumab plus MGD013",
          "interventionNames": [
            "Biological: enoblituzumab",
            "Biological: MGD013"
          ]
        }
      ],
      "interventions": [
        {
          "type": "BIOLOGICAL",
          "name": "enoblituzumab",
          "description": "anti-B7-H3 antibody",
          "armGroupLabels": [
            "Experimental Arm 1",
            "Experimental Arm 2"
          ],
          "otherNames": [
            "MGA271"
          ]
        },
        {
          "type": "BIOLOGICAL",
          "name": "MGA012",
          "description": "anti-PD-1 antibody",
          "armGroupLabels": [
            "Experimental Arm 1"
          ],
          "otherNames": [
            "INCMGA00012"
          ]
        },
        {
          "type": "BIOLOGICAL",
          "name": "MGD013",
          "description": "PD-1 X LAG-3 bispecific DART protein",
          "armGroupLabels": [
            "Experimental Arm 2"
          ]
        }
      ]
    },
    "outcomesModule": {
      "primaryOutcomes": [
        {
          "measure": "Overall Response Rate (Modules X and Y)",
          "description": "Proportion of patients with best overall response of complete response (CR) plus partial response (PR) per RECIST 1.1",
          "timeFrame": "2 years"
        },
        {
          "measure": "Incidence of Adverse Events as assessed by CTCAE v 4.03 (Modules X and Y)",
          "description": "Evaluation of adverse events and serious adverse events",
          "timeFrame": "Up to 30 days after last dose of study drug"
        }
      ],
      "secondaryOutcomes": [
        {
          "measure": "Progression-free Survival - (Modules X and Y)",
          "description": "Time from start of study treatment to the first documented disease progression per RECIST v1.1 or death due to any cause, whichever occurs first.",
          "timeFrame": "2 years"
        },
        {
          "measure": "Disease Control Rate - (Modules X and Y)",
          "description": "Percentage of patients who experienced response of CR, PR or stable disease for at least 3 months from start of study treatment",
          "timeFrame": "2 years"
        },
        {
          "measure": "Duration of Response - (Modules X and Y)",
          "description": "Time from the date of initial response to the date of first documented progression or death from any cause, whichever occurs first",
          "timeFrame": "2 years"
        },
        {
          "measure": "Immunogenicity (Module X)",
          "description": "Percentage of patients developing anti-drug antibodies to enoblituzumab and/or MGA012",
          "timeFrame": "2 years"
        },
        {
          "measure": "Immunogenicity (Module Y)",
          "description": "Percentage of patients developing anti-drug antibodies to enoblituzumab and/or MGD013",
          "timeFrame": "2 years"
        },
        {
          "measure": "Cmax (Module X)",
          "description": "Maximum serum concentration of enoblituzumab and MGA012",
          "timeFrame": "2 years"
        },
        {
          "measure": "Ctrough (Module X)",
          "description": "Trough serum concentration of enoblituzumab and MGA012",
          "timeFrame": "2 years"
        },
        {
          "measure": "Cmax (Module Y)",
          "description": "Maximum serum concentration of enoblituzumab and MGD013",
          "timeFrame": "2 years"
        },
        {
          "measure": "Ctrough (Module Y)",
          "description": "Trough serum concentration of enoblituzumab and MGD013",
          "timeFrame": "2 years"
        }
      ]
    },
    "eligibilityModule": {
      "eligibilityCriteria": "Inclusion Criteria:\n\n* Histologically proven, recurrent or metastatic SCCHN not curable by local therapy\n* No prior systemic therapy for SCCHN in the recurrent or metastatic setting (with the exception of systemic therapy completed \\> 6 months prior of given as part of multimodal treatment for locally advanced disease)\n* Primary tumor locations of oropharynx, oral cavity, hypopharynx, or larynx\n* At least one radiographically measurable lesion\n* HPV test results available (positive and negative eligible)\n* ECOG Performance status of 0 or 1\n* Adequate end organ function\n* Positive PD-L1 expression level (CPS â‰¥ 1%)\n\nExclusion Criteria:\n\n* Disease suitable for local therapy administered with curative intent\n* Progressive disease within 6 months of completion of curatively intended systemic treatment for locoregionally advanced SCCHN\n* Radiation or other non-systemic therapy within 2 weeks of first dose of study drug\n* Diagnosis of immunodeficiency, or use of immunosuppresive therapy within 14 days of first dose of study drug",
      "healthyVolunteers": false,
      "sex": "ALL",
      "minimumAge": "18 Years",
      "stdAges": [
        "ADULT",
        "OLDER_ADULT"
      ]
    },
    "ipdSharingStatementModule": {
      "ipdSharing": "NO"
    }
  },
  "derivedSection": {
    "miscInfoModule": {
      "versionHolder": "2026-02-04"
    },
    "conditionBrowseModule": {
      "meshes": [
        {
          "id": "D006258",
          "term": "Head and Neck Neoplasms"
        },
        {
          "id": "D000077195",
          "term": "Squamous Cell Carcinoma of Head and Neck"
        },
        {
          "id": "D007822",
          "term": "Laryngeal Neoplasms"
        }
      ],
      "ancestors": [
        {
          "id": "D009371",
          "term": "Neoplasms by Site"
        },
        {
          "id": "D009369",
          "term": "Neoplasms"
        },
        {
          "id": "D002294",
          "term": "Carcinoma, Squamous Cell"
        },
        {
          "id": "D002277",
          "term": "Carcinoma"
        },
        {
          "id": "D009375",
          "term": "Neoplasms, Glandular and Epithelial"
        },
        {
          "id": "D009370",
          "term": "Neoplasms by Histologic Type"
        },
        {
          "id": "D010039",
          "term": "Otorhinolaryngologic Neoplasms"
        },
        {
          "id": "D007818",
          "term": "Laryngeal Diseases"
        },
        {
          "id": "D012140",
          "term": "Respiratory Tract Diseases"
        },
        {
          "id": "D012142",
          "term": "Respiratory Tract Neoplasms"
        },
        {
          "id": "D010038",
          "term": "Otorhinolaryngologic Diseases"
        }
      ]
    }
  },
  "hasResults": false
}